Nothing To SAVOR For Bristol/AZ From Phase IV Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol and AstraZeneca announced mixed results from a post-marketing study for their diabetes drug Onglyza that will likely have no commercial ramifications for the drug, which has been a disappointment since its launch in 2009.
You may also be interested in...
Alogliptin, Saxagliptin Show Neutral CV Effects In Outcomes Studies
In separate trials, Takeda’s Nesina and BMS/AstraZeneca’s Onglyza demonstrated neither cardiovascular benefit nor harm in type 2 diabetics at increased risk for such events. The DPP-4 inhibitors also were not associated with increased rates of pancreatitis, which has been a safety concern for the class.
Alogliptin, Saxagliptin Show Neutral CV Effects In Outcomes Studies
In separate trials, Takeda’s Nesina and BMS/AstraZeneca’s Onglyza demonstrated neither cardiovascular benefit nor harm in type 2 diabetics at increased risk for such events. The DPP-4 inhibitors also were not associated with increased rates of pancreatitis, which has been a safety concern for the class.
ADA 2013: Major Players Present Data On Insulins, GLP-1s, SGLT-2s
The annual ADA conference will include data from a slew of companies, but analysts are most interested in the presentations from the biopharmas that already dominate the market and are expected to maintain their market share in the long-term.